Free Trial
NASDAQ:APRE

Aprea Therapeutics Q3 2023 Earnings Report

Aprea Therapeutics logo
$1.89 -0.04 (-2.07%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$1.83 -0.06 (-3.39%)
As of 07/25/2025 06:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aprea Therapeutics EPS Results

Actual EPS
-$0.86
Consensus EPS
-$1.08
Beat/Miss
Beat by +$0.22
One Year Ago EPS
N/A

Aprea Therapeutics Revenue Results

Actual Revenue
$0.32 million
Expected Revenue
$0.25 million
Beat/Miss
Beat by +$70.00 thousand
YoY Revenue Growth
N/A

Aprea Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Thursday, November 9, 2023
Conference Call Time
11:00AM ET

Upcoming Earnings

Aprea Therapeutics' Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Aprea Therapeutics Earnings Headlines

Aprea Therapeutics Inc (APRE) - Investing.com
Aprea Therapeutics, Inc. (APRE) - Yahoo Finance
Altucher: Turn $900 into $108,000 in just 12 months?
Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this marks the beginning of “Trump’s Great Gain,” a new crypto bull phase driven by emerging federal policies. He believes certain altcoins could turn $900 into $108,000 — and reveals everything in a new presentation.
See More Aprea Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aprea Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aprea Therapeutics and other key companies, straight to your email.

About Aprea Therapeutics

Aprea Therapeutics (NASDAQ:APRE), a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

View Aprea Therapeutics Profile

More Earnings Resources from MarketBeat